Kämpe, Anders http://orcid.org/0000-0002-1829-3855
Suvisaari, Jaana http://orcid.org/0000-0001-7167-0990
Lähteenvuo, Markku http://orcid.org/0000-0002-7244-145X
Singh, Tarjinder
Ahola-Olli, Ari
Urpa, Lea http://orcid.org/0000-0002-8712-3518
Haaki, Willehard
Hietala, Jarmo
Isometsä, Erkki
Jukuri, Tuomas
Kampman, Olli
Kieseppä, Tuula
Lahdensuo, Kaisla
Lönnqvist, Jouko
Männynsalo, Teemu
Paunio, Tiina http://orcid.org/0000-0002-5560-0666
Niemi-Pynttäri, Jussi
Suokas, Kimmo http://orcid.org/0000-0001-6296-6343
Tuulio-Henriksson, Annamari
Veijola, Juha
Wegelius, Asko
Kyttälä, Aija
Ahola-Olli, Ari
Toivola, Auli
Neale, Benjamin
Shen, Huei-yi
Västrik, Imre
Tiihonen, Jari
Hietala, Jarmo
Lönnqvist, Jouko
Veijola, Juha
Lahdensuo, Kaisla
Häkkinen, Katja
Daly, Mark
Holm, Minna
Ristiluoma, Noora
Kajanne, Risto
Hyman, Steven E.
Singh, Tarjinder
Daly, Mark
Taylor, Jacob
Kendler, Kenneth S. http://orcid.org/0000-0001-8689-6570
Palotie, Aarno http://orcid.org/0000-0002-2527-5874
Pietiläinen, Olli http://orcid.org/0000-0003-4387-1861
,
Funding for this research was provided by:
Svenska Sällskapet för Medicinsk Forskning (PD20-0190)
Sigrid Juséliuksen Säätiö
Academy of Finland
Instrumentariumin Tiedesäätiö
Jenny ja Antti Wihurin Rahasto
Article History
Received: 21 July 2023
Revised: 28 February 2024
Accepted: 4 March 2024
First Online: 1 April 2024
Competing interests
: AO is a shareholder and employee of Abomics, a company offering pharmacogenetics-related ICT-solutions and consultation services. MD is a member of the Pfizer Finland FinnGen Advisory Board and a founder of Maze Therapeutics.
: The study was approved by the Ethics Committee of the Hospital District of Helsinki and Uusimaa (Reference number 202/13/03/00/15). All participants were 18 years or older at the time of inclusion, and all have given written informed consent.